1998 Fiscal Year Final Research Report Summary
Suppressive effects of adrenomedullin, a novel hypotensive peptide, on the progression of pulmonary hypertension
| Project/Area Number |
09670803
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | KYOTO UNIVERSITY |
|---|
Principal Investigator |
YOSHIBAYASHI Muneo Kyoto University, Graduate School of Medicine, Assistant Professor, 医学研究科, 助手 (80273449)
|
|---|
| Project Period (FY) |
1997 – 1998
|
| Keywords | adrenomedullin / pulmonary hypertension / congenital heart disease |
|---|
| Research Abstract |
1. Four-week-old male Wistar rats (n=20) were given a subcutaneous injection of 60 mg/kg monocrotaline. Since then, rat adrenomedullin (AM) of 5 mug/day was administered subcutaneously for 3 weeks to the half of them (PH-AM group ; n=10), and 0.9% saline in the same way to the other half (PH-saline group ; n=10). After the administration for 3 weeks, right ventricular systolic pressure (RVP) was measured with a catheter inserted through the right jugular vein and blood was collected from the catheter. The plasma AM concentration was measured using the radioimmunoassay from the sample. Then the rat was sacrificed and the ratio of right ventricular weight to body weight (RV/BW) and the ratio of medial thickness to external diameter of the pulmonary artery (%MT) were measured. The plasma AM concentration in the PH-AM group was significantly elevated than that in the PH-saline group. RVP, RV/BW and %MT in the PH-AM group were significantly lower than those in the PH-saline group. These results indicate that AM suppresses the progression of pulmonary hypertension in rats treated with monocrotaline.
2. Plasma AM concentrations were measured in pediatric patients with cardiovascular diseases. Plasma AM concentrations were elevatcd in patients with pulmonary hypertension and in those with congenital cyanotic heart disease, suggesting that adrenomedullin may be involved in cardiovascular regulation in these diseases.
|
